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Abstract: The oligomycin-sensitivity conferring protein (OSCP) of the mitochondrial FOF1 
ATP synthase has long been recognized to be essential for the coupling of proton transport 
to ATP synthesis. Located on top of the catalytic F1 sector, it makes stable contacts with 
both F1 and the peripheral stalk, ensuring the structural and functional coupling between FO 
and F1, which is disrupted by the antibiotic, oligomycin. Recent data have established that 
OSCP is the binding target of cyclophilin (CyP) D, a well-characterized inducer of the 
mitochondrial permeability transition pore (PTP), whose opening can precipitate cell death. 
CyPD binding affects ATP synthase activity, and most importantly, it decreases the 
threshold matrix Ca2+ required for PTP opening, in striking analogy with benzodiazepine 
423, an apoptosis-inducing agent that also binds OSCP. These findings are consistent with 
the demonstration that dimers of ATP synthase generate Ca2+-dependent currents with 
features indistinguishable from those of the PTP and suggest that ATP synthase is directly 
involved in PTP formation, although the underlying mechanism remains to be established. 
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In this scenario, OSCP appears to play a fundamental role, sensing the signal(s) that 
switches the enzyme of life in a channel able to precipitate cell death. 
Keywords: mitochondria; oligomycin-sensitivity conferring protein (OSCP);  
cyclophilin D (CyPD); FOF1 ATP synthase dimer; permeability transition pore (PTP) 
 
1. Introduction 
Mitochondria are cytoplasmic double-membrane-delimited organelles of variable size, with a 
diameter between 0.5 and 5 μm, which are organized in a dynamic network [1] and are responsible of 
the aerobic production of ATP by the oxidative phosphorylation system (OXPHOS). In addition, 
mitochondria participate in intermediary metabolism and are involved in the early stages of cell death, 
where the Ca2+-dependent permeability transition pore (PTP) plays a key role [2]. OXPHOS catalyzes 
the oxidation of fuel molecules and the concomitant synthesis of ATP via five complexes located in 
the inner mitochondrial membrane (IMM), which is highly folded into cristae. Briefly, Complexes I, 
III and IV of the respiratory chain catalyze a sequential series of redox reactions, resulting in the 
reduction of oxygen to water; at the same time, they pump protons across the IMM into the 
intermembrane space (IMS), generating a proton electrochemical gradient that provides the driving 
force for the synthesis of ATP from ADP and inorganic phosphate (Pi) within Complex V (or FOF1 
ATP synthase). 
Intriguingly, recent data suggest that Complex V has a second function, as it is able to generate 
Ca2+-dependent currents with features indistinguishable from those of the PTP, as assessed after 
isolation in the form of dimers, which represent its physiological state in the IMM [3]. The enzyme of 
life appears therefore to be directly involved in PTP formation to stimulate cell death [4]. The OSCP 
(oligomycin-sensitivity conferring protein) subunit of ATP synthase appears to play a unique role, 
being the site of interaction of cyclophilin (CyP) D, a matrix protein that favors PTP opening, as will 
be discussed below. CyPD is also the downstream effector of kinase signaling pathways, which target 
the PTP, such as hexokinase II and the Akt-ERK-GSK3 axis, whose dysregulation is a hallmark of 
several neoplastic cell models [5]. Post-translational modifications (PTMs) of OSCP have also been 
reported [6–8], but their functional implications are still to be defined. These observations suggest that 
CyPD-OSCP interaction mediates a survival or death signal modulating the PTP closure/opening, 
although the underlying mechanism remains to be establish. 
The IMM also contains many transporters or carriers that translocate nucleotides, inorganic ions 
and metabolites, including phosphate, thereby determining the compartmentalization of the metabolic 
functions of mitochondria. The mitochondrial proteome ranges between about 800 (yeast) and  
1500 (human) different proteins [9], with relevant differences between organs [10]. Although the 
majority of mitochondrial proteins is encoded in the nucleus and post-translationally imported into the 
organelle by a complex protein-import machinery [11], some subunits of the OXPHOS (13 in humans) 
are encoded by the mitochondrial genome (mtDNA), which is present in several copies per organelle 
and is exclusively maternally inherited. 
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Defects in mitochondrial DNA (mtDNA) have been associated with mitochondrial diseases, which 
encompass a wide variety of degenerative diseases and may also play a role in aging and cancer [12]. 
Complex V deficiency due to mutations in the mtDNA-encoded subunits a and A6L is a very rare 
OXPHOS deficiency. Phenotypic variations in disease severity depend mainly on the fraction of 
mutated mtDNA percent (i.e., the level of heteroplasmy), as observed in Maternally inherited Leigh 
syndrome (MILS) and neuropathy, ataxia and retinis pigmentosa (NARP) syndrome, caused by subunit 
a (MT-ATP6) mutations. Mitochondrial diseases due to genetic defects in the nuclear genes affecting 
one structural subunit, one assembly and one ancillary factor have also been described [13]. Deficiency 
in ATP synthesis appears to be the main pathogenic factor, although other mechanisms are involved, 
such as the generation of reactive oxygen species (ROS) [14–16]. On the other hand, the novel 
function of ATP synthase in PTP formation makes this picture much more complex, considering the 
role played by PTP and by its dysregulation in a variety of diseases characterized by altered cell death, 
which include ischemia-reperfusion injury of the heart and brain, muscular dystrophies, 
neurodegeneration and cancer [5,17]. 
2. ATP Synthase Structure 
The mitochondrial ATP synthase is a 600-kDa multisubunit complex. Its molecular structure and 
catalytic mechanism were understood by the seminal work of the Nobel Laureates, Mitchell, Boyer 
and Walker [18–20], which revealed its complexity and the functional steps driving the synthesis of 
ATP. In addition to the IMM, ATP synthase is present in the thylakoid membrane of chloroplasts, and 
in the plasma membrane of bacteria and mammalian cells, although with opposite orientation [21,22]. 
It is well conserved, considering its structural complexity and the early divergence of bacteria, plants 
and animals [23]. Proton translocation and synthesis of ATP from ADP and Pi are coupled by a unique 
mechanism: subunit rotation. The electrochemical energy contained in the proton gradient is converted 
into mechanical energy in the form of subunit rotation and back into chemical energy as ATP [24–27]. 
The enzyme is also able to work in the direction of ATP hydrolysis, sustaining the formation of the 
proton gradient, when there is a loss of membrane potential. In both directions, Mg2+ is essential for 
catalysis, and it can be replaced by other divalent cations, such as Mn2+ and Co2+. Intriguingly, Ca2+ 
ions, which induce PTP formation, only sustain ATP hydrolysis by F1, which is not coupled to proton 
translocation both in bacteria [28] and in mammals [29]. 
Traditionally, ATP synthase is divided into two subcomplexes, the membrane-embedded FO 
subcomplex, through which the protons flow, and the soluble F1 subcomplex. The latter is always 
composed of three copies of each of subunits α and β (which carry the nucleotide binding sites) and 
one each of subunits γ, δ and ε (which constitute the central stalk of the complex). Subunit γ rotation 
within α3β3 takes each of the three β subunits through the conformations, βDP, βTP and βE, thereby 
synthesizing three Mg2+-ATP molecules during each 360° rotation [30]. 
The inhibitor protein, IF1, binds to F1, at a α/β interface, under energy deficiency [31,32], i.e., at low 
pH and membrane potential, when the enzyme hydrolyzes rather than synthesizes ATP. Therefore, IF1, 
which is evolutionarily conserved from yeast to mammals, is considered responsible for the beneficial 
(at least partial) inhibition of FOF1 during ischemia both in in vitro experimental models, as well as  
in vivo [33], as also demonstrated by our group in anaesthetized open-chest goat heart [34]. 
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Unexpectedly, IF1-knockout mice grew without defects, but their behavior against stressful situations 
have not been tested [35]. 
In the simplest form of the enzyme, such as that of bacteria, like Escherichia coli, FO consists of 
three different subunits, a, b and c, with stoichiometry ab2c9–12 [23]. Subunits a and c form the proton 
channel, while subunit b links the proton channel to F1. The animal mitochondrial FO sector has a more 
complicated structure, since ten subunits have been identified, a, b, c, F6, d, e, A6L, f, g and  
OSCP [36]. The a, b and c subunits share great similarity with the bacterial subunits, except for subunit 
c stoichiometry which comprises only eight copies, thus reducing the bioenergetic cost of ATP  
synthesis [37], whereas the remaining subunits are unique to the mitochondrial complex (Table 1). The 
membrane-embedded part of FO comprising subunits e, f, g and A6L is connected to F1 by a complex 
peripheral stalk, composed by one copy each of subunit b, d, F6 and OSCP, which is important to 
prevent the co-rotation of α and β subunits with γ and, therefore, the loss of enzyme efficiency. OSCP 
is a 213-amino acid protein (including the 23 amino acid mitochondrial leader sequence) located on the 
top of F1 [38], which is analogous to E. coli δ-subunit and is highly conserved among mammals [39]. 
Besides these subunits, in beef, rat and man, two hydrophobic proteins, namely a 6.8-kDa proteolipid 
(called MLQ) [40,41], and α1 acid glycoprotein/diabetes-associated protein in insulin-sensitive tissue 
(called AGP/DAPIT) [42], are associated with the FO. All together, the mitochondrial membrane 
domain is constituted by approximately 30 trans-membrane α-helices [43] (Figure 1). 
Table 1. Equivalence of subunits of ATP synthase from different sources 1. 
Mitochondria E. coli,  
P. modestum and A. woodii 
Chloroplast, cyanobacteria 2 
and rhodobacteria 3 Bovine Yeast 
α α α α 
β β β β 
γ γ γ γ 
δ δ ε ε 
ε ε - - 
OSCP OSCP δ δ 
b 4 or b B 4 b and b' (I and II) 
A6L 8 - - 
F6 h - - 
a 6 or a a a (IV) 
c 9 or c c c (III) 
d d - - 
e e - - 
f f - - 
g g - - 
- i/j - - 
- k - - 
MLQ - - - 
AGP/DAPIT - - - 
1 Subunit equivalence is based on sequence homology; 2 Synechococcus; 3 Rhodospirillum rubrum and 
Rhodopseudomonas blastica; 4 ATP synthase from E. coli and P. modestum have two copies of the b subunit 
and ATP synthase from chloroplasts, cyanobacteria and rhodobacteria have one copy of each b and b'. The b 
and b' are homologous; -, no subunit equivalence. 
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Figure 1. Schematic representation of FOF1 ATP synthase as a monomer. 
 
ATP synthase is commonly isolated as a functional monomer, but this is not the physiological state 
in yeast, mammalian and plant mitochondria [44,45]. Biochemical and electron microscopy studies 
demonstrated that within the IMM, the enzyme is organized in dimers associated with forming long 
rows of oligomers located at the cristae ridges to maintain a high local curvature [3] and normal cristae 
morphology [46,47]. Dimers interact within the IMM through the FO subunits [48] with the peripheral 
stalks turned away from each other [38]. The proposed roles of the ATP synthase oligomers are higher 
efficiency and higher stability [3,49]. Consistently, in aged mitochondria of Podospora anserina, the 
disappearance of the typical IMM architecture and impairment of ATP synthesis were concomitant  
to ATP synthase dimer dissociation and formation of IMM vesicles [50]. Intriguingly, electron 
tomography evidenced the binding of a bell-shaped protein, possibly CyPD, between the FO-FO of 
dimers at the bases of the peripheral stalks in early-vesicular mitochondria followed by its dissociation 
from monomers in aged mitochondria. These observation prompted the authors to propose a role of 
CyPD in promoting dimer dissociation. We found that CyPD interacts with OSCP in the ATP synthase 
dimers promoting PTP formation [2,4], as will be discussed below. If CyPD binding between the two 
FO will be confirmed by further investigation, the existence of distinct CyPD binding sites on ATP 
synthase dimers may be proposed. 
The structural properties of dimers were initially characterized in yeast, where genetic approaches, 
cross-linking analyses and electron microscopy images established preferential interactions within  
the IMM, mainly through the Su6 [51], Su4 [52], e [53] and g subunits [54], which formed Su6/Su6, 
Su4/Su4 and e/g interactions, and also through the yeast-specific FO subunits, h and i [55]. In keeping 
with its general occurrence, the involvement of subunits a [56], e [57] and g [44] in ATP synthase 
dimerization has been demonstrated also in mammals. In addition, a second interface (named the 
oligomerization interface) has been described in yeast; this interface was stabilized through e/e and g/g 
interactions allowing oligomer formation [45]. However, the existence of an oligomerization interface 
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has been criticized based on electron cryotomography data of mitochondria from different sources, 
including bovine heart, which evidenced variable distance between dimers, making direct protein 
contacts difficult [3]. Moreover, electron cryotomography showed that dimers of all species display 
fixed angles between two F1-F1 with an angle >70° [3], in contrast with previous single-particle 
electron microscopy images, which indicated angles ranging from 40° [58,59] to 70°–90° [48,60].  
It has been proposed that the 40° dimers form upon the inhibitory binding of IF1 [3], which was 
contained in considerable amounts in isolated dimers [58]. However, although IF1 was not essential for 
ATP synthase dimerization both in yeast [61] and mammals [62], we found that in cardiomyoblasts 
undergoing cardiac differentiation, IF1 binding promoted dimer/oligomer stabilization, possibly 
through a non-inhibitory interaction, which remains to be clarified. In fact, in differentiated cells, an 
increased IF1 binding occurred in parallel with an increase of ATP synthesis, as already reported in 
human HeLa cells [63] overexpressing IF1, as well as of ATP hydrolysis [64]. Intriguingly, a  
pH-independent interaction of IF1 with OSCP has been described [65], whose functional implication 
remains to be established. A stabilizing effect on bovine ATP synthase dimers has been also reported 
for the matrix metalloprotein, called factor B, which interacts with the e and g subunits of FO [66]. 
3. OSCP: Location and Structure 
It has long been established that OSCP is essential for conferring sensitivity to the inhibition of 
ATP synthase by the antibiotic, oligomycin [67], although oligomycin does not bind OSCP. Sensitivity 
to oligomycin can be defined in two contexts. The first relates to the “coupling” of the enzyme assayed 
as the oligomycin-sensitive ATP hydrolytic (ATPase) activity. It is a measure of the structural integrity 
of the enzyme, since detachment of F1 from FO leads to a decrease in oligomycin-sensitive ATPase  
activity [68–72]. Under these conditions, ATP hydrolysis by F1 still takes place, but ATP hydrolysis is 
no longer coupled to proton translocation, and the sensitivity to oligomycin is lost, demonstrating that 
oligomycin inhibits proton transport in FO, thus affecting the Vmax of ATP hydrolysis, only when FO is 
correctly bound to F1, i.e., in the coupled enzyme [70]. In this context, depletion/reconstitution studies 
in isolated membranes demonstrated that OSCP is absolutely necessary in coupling proton 
translocation to ATP synthesis [71]. In keeping with this key function of the subunit, yeast OSCP 
knockouts failed to survive under normal growth conditions [73]. 
The second context relates to the ability of the assembled ATP synthase complex to bind 
oligomycin. In yeast, the oligomycin resistance phenotype is conferred by mutations in one of the two 
mitochondrially encoded subunits, a (Su6) and c (Su9), indicating that the oligomycin-binding site 
encompasses the C-terminal region of Su6 and the transmembrane domains of Su9 [74]. This is 
consistent with the role of these subunits in proton translocation through FO, which requires the 
concerted action of both. 
Boyle and Colleagues have examined the effect of a single residue change at a conserved glycine 
(Position 166) of yeast OSCP [75]. A G166N mutant allowed enzyme assembly into functional 
complexes and was able to grow on ethanol, albeit with a slower generation time. Mutant cells 
demonstrated a relative insensitivity to oligomycin during State 3 respiration, as well as a passive leak 
of protons across the IMM. Moreover, ATP synthase complexes containing the G166N mutation were 
found to be unstable, being more susceptible to dissociation than complexes containing native OSCP. 
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These properties suggested that altered protein-protein interactions between OSCP and the α3β3 
hexamer partially uncoupled the enzyme. Interestingly, binding of 17β-estradiol to OSCP promoted an 
intrinsically uncoupled state of ATP synthase, while the enzyme was actually catalyzing the ATP 
synthesis in rat liver mitochondria [76]. Fluorescence resonance energy transfer (FRET) measurements 
have documented the stress developing between F1 and OSCP during ATP hydrolysis, which appears 
to match its role as part of the peripheral stalk [77]. 
Intriguingly, OSCP binds isolated F1 in bovine, but not yeast, mitochondria [70,78] Moreover,  
in organello pulse-labeling and pulse-chase experiments run in yeast seem to indicate that OSCP 
binding is the last step in the assembly of FOF1 and that it occurs independently of the two pathways 
that converge to form the whole ATP synthase from the F1/Su9-ring and Su6/Su8/peripheral stalk 
subcomplexes [79]. Consistent with these data, reducing OSCP levels in human cells did not alter the 
expression of other FOF1 subunits, as well as of the respiratory chain complexes [4,78]. Interestingly, 
in a model of Leigh syndrome obtained in a conditional knockout mouse heart for the mtDNA 
regulator, Lrpprc (leucine-rich pentatricopeptide repeat containing protein), the appearance has been 
recently observed of ATP synthase subcomplexes lacking OSCP and A6L. These subcomplexes 
contained a high amount of IF1, which blocked the ATP hydrolysis at physiological pH, counteracting 
the overall impairment of ATP production [16]. 
Rees and Colleagues [80] established the physical location of OSCP in the peripheral stalk by 
analyzing the crystal of a F1-peripheral stalk subcomplex and demonstrated that the subunit sits on top 
of the F1 domain (see Figure 1), in agreement with earlier experiments [81]. Its N-terminal domain 
(Residues 1–113) contains six α-helices and shows a similar fold to that of the N-terminal fragment of 
recombinant OSCP analyzed by NMR [82]. Helices 1 and 5 provide the binding site: (i) for  
Residues 6–17 of subunit αE (which contacts βE in α3β3 subcomplex), largely via hydrophobic 
interactions and two possible charge-charge interactions through R15 and E91; and (ii) for E7 and R94 
of subunits α and OSCP, respectively [80]. These interactions are similar to those determined with 
isolated OSCP and synthetic peptides from the N-terminals of mitochondrial and bacterial α  
subunits [81,83]. There is another region of interaction involving Residues 1–14 of the OSCP with the 
F1 N-terminal β-barrel domains of the βDP-subunit [80]. 
The structure of the C-terminal domain of OSCP, which is unstructured in the isolated protein [82], 
consists of a β-hairpin, which precisely locates along the α/β interface [38], followed by two α-helices, 
H7 and H8 [80]. H8 of the OSCP forms a three-helix bundle with the N-terminal α-helix of F6 and a 
segment of subunit b. The C-terminal of subunit b also packs against helix H7 of the OSCP, resulting 
in an extensive interface between OSCP and subunits b and F6. 
4. Post Translational Modifications of OSCP Subunit 
Information on post-translational modifications (PTM) of ATP synthase subunits has increased with 
the development of new techniques, such as PTM-specific mass spectrometry (MS)-based methods, 
selective dyes (ProQ Diamond) and specific antibodies. The association of several of these PTMs  
with specific biological processes, i.e., PDGF-mediated phosphorylation of the δ subunit [84,85], or  
diseases (such as type 2 diabetes [86]) has been found. The challenge is now to find direct  
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functional implications for these PTMs. The OSCP subunit has been reported to be glycosylated [7], 
phosphorylated [6,87–90] and acetylated [8,91] (Table 2). 
Table 2. Post-translational modifications of OSCP. 
Modification Method Residue Organism/Tissue Reference 
Acetylation 
MS 1 
K60, K70, K159, K162, 
K172, K176, K192 
Mouse/Liver [91] 
K Ab  Human 143B osteosarcoma cells [8] 
Phosphorylation 
ProQ  Pig/Heart [6] 
PhosTag  Pig/Heart [87] 
32P  Pig/Heart [90] 
MS T145 Pig/Heart [89] 
MS S155 Human/Muscle [88] 
Glycosylation Leptin resin  Bovine/Heart [7] 
Ubiquitination Ub Ab  Human colon cancer cells [92] 
1 Abbreviations: MS, mass spectrometry; K Ab, anti-lysine antibody; Ub Ab, anti-ubiquitin antibody.  
Although the glycosylation of secreted, membrane and nucleocytosolic proteins has been well 
studied, information on the glycosylation of mitochondrial proteins is limited [93,94]. Recently, 
different authors have proposed that several proteins with mitochondrial function or with 
mitochondrial-annotation and, thus, putative mitochondrial function may be glycosylated [95–98]. 
Berninsone and Burnham-Marusich [7] identified glycosylated isoforms of OSCP and the d subunit 
in bovine heart mitochondria by using a leptin resin. The same authors also detected a glycosylated 
isoform of the ATP synthase α subunit in bovine heart tissue, in a primate cell line (COS-7) and in the 
Caenorhabditis elegans primary embryonic cell line [99]. These results indicate that glycosylated 
isoforms of proteins with established mitochondrial function exist and may be more common than 
previously appreciated. Computational prediction of OSCP (P13621 sequence) glycosylation sites 
revealed two O-glycosylation sites, one of which is near to Helix 6, contacting αE [80] (NetOGlyc 4.0 
algorithm [100]), thus suggesting an involvement in the modulation of enzyme activity. Interestingly, 
in rat cardiac myocytes, an increase of O-glycosylation of Complex I, III and IV is associated with 
impaired respiratory activity [96]. Taken together, these findings open questions about where in the 
cell and, consequently, by which glycosyltransferases these proteins, including OSCP, become 
glycosylated and the nature of glycosylation (the attachment site and structure of glycans). 
Phosphorylation of OSCP was reported for the first time by Hopper et al. [6], who analyzed the 
phosphoproteome of the mitochondrial matrix in porcine heart, using the phosphorylation targeted dye, 
ProQ Diamond, in conjunction with 2D gel and mass spectrometry. A phosphorylated form of OSCP 
has been later found also in porcine heart by the Balaban group, who extensively studied mitochondrial 
phosphoproteome with PhosTag and 32P labeling (for a review of ATP synthase phosphorylation,  
see [89]). In particular, the OSCP residues, Ser155 and Thr145, have been found phosphorylated in 
human skeletal muscle and pig heart, respectively [88,101]. Their location near the αE subunit suggests 
that phosphorylation may participate in the regulation of motor function, but no evidence has been yet 
reported. Nevertheless, and in spite of these advances, kinases and phosphatases involved in ATP 
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synthase phosphorylation are still poorly defined, and further work will be needed to understand the 
consequences of phosphorylation on enzyme activity. 
The first extensive proteomic study of mitochondrial protein acetylation was performed in mouse 
liver mitochondria [91] and revealed that more than 20% of mitochondrial proteins contain acetylated 
lysine residues, including OSCP and the other peripheral stalk subunits, the F1 α, β, γ subunits and the 
FO g and A6L subunits, for which the acetylated sites have been identified. More recently, acetylation 
of α and OSCP subunits was confirmed by Wei et al. [8], who discovered that Sirtuin3, which belongs 
to a large family of NAD+-dependent protein deacetylases, interacts with OSCP and activates the 
enzyme through deacetylation of α and OSCP subunits. Such a finding is consistent with the ability  
of acetylation to neutralize the positive charge of lysine residues, as well as to increase the 
hydrophobicity and size of the lysine side chains, causing potential alterations of the protein propensity 
to interact with other proteins. Thus, the acetylation of OSCP can induce a conformational change of 
the protein itself or prevent complex formation with other proteins. The relevance of acetylation was 
confirmed by the observation that potentially every major metabolic enzyme is acetylated, both inside 
and outside the mitochondria [102,103]. 
Interestingly, selective immunoprecipitation of OSCP from mitochondrial lysates revealed that 
OSCP is ubiquitinated in colon cancer cells (human COLO 205 cell line) together with high levels of 
the expression of Hsp90 [92]. OSCP ubiquitination was not observed in an MS analysis of mouse 
heart, where, instead the α, β, γ and b subunits were found to be ubiquitinated [104], suggesting a 
specific role of OSCP ubiquitination in cancer cells. 
In summary, several PTMs have been identified in the OSCP subunit, especially phosphorylation 
and acetylation, for which specific sites have been found (Table 2). However, for most of them, the 
functional consequences are still unknown, as well as the enzymes involved in these modifications. 
5. OSCP Interactors: CyPD and PTP Formation 
ATP synthase activity is regulated by the reversible association of a variety of regulatory peptides, 
including CyPD. Beside the already mentioned IF1, an inhibitory interaction with protein kinase Cδ at 
subunit d of the lateral stalk has been described, whose disruption attenuated the injury resulting from 
prolonged oxygen deprivation in neonatal cardiac myocytes [105]. Conversely, the Ca2+-dependent 
association of S100A1 with F1 improved the enzyme performance in cardiomyocytes [106]. Binding of 
Bcl-XL to the β subunit and binding of Factor B to the membrane-embedded part of FO increased  
the aerobic ATP production by blocking a proton leak in healthy neurons [107] and in animal 
mitochondria [66,108], respectively. In addition, three new interactors have been described that 
selectively bind OSCP, i.e., the already mentioned Sirtuin3, CyPD and, possibly, p53 [109]. 
Sirtuins control a variety of cellular function via their NAD+-dependent deacetylase activity [110]. 
Sirtuin3 is the best characterized sirtuin in mitochondria and has emerged as a major regulator of 
mitochondrial metabolism and energy homeostasis through mitochondrial protein deacetylation [111]. 
As already mentioned, Wei and co-workers discovered that endogenous Sirt3 interacts with OSCP and 
mediates the deacetylation of the α and OSCP subunits. Interestingly, these authors found that ATPase 
acetylation and Sirtuin3 expression are altered in human cells harboring a pathogenic mtDNA mutation 
(the 4977 bp deletion), as well as under increased ROS production in human cells [8]. 
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p53 is a transcription factor rapidly activated in response to multiple stresses regulating hundreds of 
genes implicated in cell cycle, senescence, apoptosis, metabolism and DNA repair [112]. For a human 
cell model expressing mitochondrially-targeted p53 (with a vector in which the sequence encoding a 
mitochondrial import leader was fused to the 5' end of wild-type p53), a transcription-independent 
activity of p53 able to increase oxygen consumption and to decrease ROS production in the absence of 
acute stress has been recently reported. By immunoprecipitation and mass spectrometry, the authors 
demonstrated that p53 interacts with OSCP, taking part in the assembly or stabilization of the mature 
FOF1 complex, thus suggesting that the mitochondrial fraction of p53, although very low, may be an 
important regulator of mitochondrial physiology, potentially exerting tumor suppression [109]. 
However, interaction domains between p53 and Sirt3 with OSCP have been not yet been determined. 
CyPD belongs to a ubiquitous protein family with peptidyl-prolyl cis-trans isomerase (PPIase) 
activity, which is inhibited by cyclosporin (Cs) A [113]. CyPs share a common domain of 
approximately 109 amino acids, the CyP-like domain [17,114]. In spite of this, CyPs do not play a 
general role in protein folding, and the existence of tissue- and organelle-specific isoforms with the 
proper targeting and/or retention sequence(s) suggests that each CyP regulates a restricted number of 
unique partner proteins [114,115]. 
CyPD is the unique mitochondrial isoform of CyPs in mammals and is involved in the regulation of 
the PTP, but is not a structural pore component. PTP is a conserved high-conductance channel  
located in the inner mitochondrial membrane (IMM) that allows the diffusion of solutes up to about  
1500 Da [116]. PTP openings of a short duration lead to transient IMM depolarization [117] and may 
be caused by physiological stimuli [118]; while long-lasting openings cause permanent depolarization, 
loss of ionic homeostasis, depletion of matrix pyridine nucleotides, resulting in respiratory inhibition, 
and the generation of reactive oxygen species (ROS). Moreover, the matrix swelling occurs as a 
consequence of its high oncotic pressure, and the outer mitochondrial membrane (OMM) may disrupt 
with the release of pro-apoptotic intermembrane proteins, including cytochrome c. Thus, long-lasting 
PTP opening may represent a point of no return in cell commitment to death, which can occur either 
through apoptosis (if enough ATP is present to sustain caspase activity) or through necrosis  
(when ATP is depleted) [5]. 
The role of CyPD as a PTP inducer was suggested by the demonstration that addition of CsA to 
isolated mitochondria desensitizes the PTP, in that pore opening requires about twice the Ca2+ load 
necessary to open the pore in the absence of CsA [119]. Genetic ablation of the Ppif gene (which 
encodes for CyPD in the mouse) has confirmed that CyPD is the mitochondrial receptor for CsA, and 
it is responsible for the modulation of the PTP, both in vitro and in vivo [120–123]. The crystal 
structure of human CypD in complex with CsA demonstrated that it is composed of eight β-strands, 
two α-helices and one 310 helix [124]. 
A major step in the mechanistic understanding of the role of CyPD in PTP regulation has been the 
discovery that CyPD masks an inhibitory site for Pi, which is the actual PTP desensitizing agent [125]. 
Furthermore, PTP modulation by CyPD is affected by CyPD phosphorylation [5], acetylation [126] 
and nitrosylation [127]. Not surprisingly, several regulatory interactions of CyPD have been reported 
in the literature, including Hsp90 and its related molecule, TRAP-1 [128], Bcl-2 [129], ERK-2/GSK-3 [5] 
and possibly p53 [130], which also seems to bind OSCP [109]. 
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The identification of CyPD interaction with the OSCP subunit of ATP synthase was an essential 
step for the identification of the PTP, whose molecular nature was still a matter of conjectures [2]. The 
previous model still postulated that PTP is formed by a supramolecular complex, including the  
voltage-dependent anion channel (VDAC) of the OMM, as well as the adenine nucleotide translocator 
(ANT) and the phosphate carrier (PiC) located in the IMM, but genetic testing has excluded this 
possibility for all of these proteins [2]. 
We observed that in mammals, CyPD binds the ATP synthase peripheral stalk in an apparent ratio 
of 1:1:1:1 with the OSCP, b and d subunits; that this interaction is favored by Pi, which exerts multiple 
effects on PTP [125], as well as on ATP synthase [131]; and that the interaction is competed by CsA 
concentrations known to displace CyPD from the IMM [132]. Importantly, CyPD preferentially binds 
to the ATP synthase dimers, causing a decrease of specific activity that can be reversed by CsA [133]. 
Consistent with a regulatory interaction, the stimulatory effect of CsA was lost in Ppif−/− 
mitochondria, indicating that it was mediated by CyPD, while the assembly of the ATP synthase was 
unaffected by CyPD ablation [133]. 
CyPD interaction with OSCP (which appears to be mostly electrostatic in nature) was confirmed by 
immunoprecipitation of OSCP from mitochondria [4]. When ATP synthase was immunoprecipitated 
from mitochondria with decreased OSCP levels, decreased levels of CyPD were detected, as well. A 
study of surface potentials and isopotential curves of CyPD and OSCP in the ATP synthase complex 
identified putative binding regions of CyPD on OSCP at the region overlapping with Helices 3 and 4, 
which represent the lowest (i.e., most negative) average surface potential regions, as shown in  
Figure 2, where OSCP in the context of ATP synthase is depicted. These helices are also the binding 
site of benzodiazepine (Bz)-423, a well-characterized inhibitor of ATP synthase (Figure 2) [78]. 
Treatment of mitochondria with Bz-423 induced CyPD displacement from ATP synthase, suggesting 
competition for a common binding site. Such localization is therefore consistent with the CyPD 
inhibitory activity of ATP synthase and may allow CyPD binding to all classes of dimers, including 
those displaying small angles between two F1, which have the peripheral stalks in contact, mutually 
hiding their subunits, except OSCP. These latter dimers probably form upon IF1 binding [3,58], i.e., 
when ATP synthase hydrolyses ATP generating high Pi, which, in turn, is necessary for CyPD  
binding [133]. Further work is needed to define the amino acids involved in these interactions. 
Consistent with the involvement of ATP synthase in PTP formation, mitochondria treated with  
Bz-423 or expressing decreased levels of OSCP also decreased the threshold Ca2+ required for PTP 
opening, revealing a striking analogy between the effects of Bz-423 and OSCP on PTP and ATP 
synthase. Direct evidence that PTP forms from ATP synthase was obtained by electrophysiology, 
which demonstrated that the addition of Bz-423 in the presence of Ca2+ to ATP synthase dimers 
isolated and incorporated in azolectin bilayers triggered Ca2+-dependent currents with features 
indistinguishable from those of the PTP [134], which were inhibited by Mg2+-ADP and by AMP-PNP 
(γ-imino ATP), a nonhydrolyzable ATP analog. Taken together, these findings prompted us to 
hypothesize that Ca2+, which is able to sustain only uncoupled ATP hydrolysis [29], replaces Mg2+ and 
induces conformational changes in FO, which could then mediate PTP formation from ATP synthase 
dimers. OSCP may thus act as a negative modulator of PTP affecting Ca2+ accessibility, except when it 
binds CyPD or Bz-423, which favor PTP formation. 
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Beyond CyPD and Ca2+, many other effectors regulate the open-closed transitions of PTP, including 
Mg2+, Mn2+, nucleotides and low pH (which favor its closure); and low membrane potential, high Pi, 
and ROS (which favor its opening) [118,135]. ROS may induce the PTP, but also form as a 
consequence of PTP opening, in a feed-forward loop that may stabilize the pore in the open 
conformation. The FOF1 ATP synthase potentially accommodates all these PTP pathophysiological 
effectors, since divalent cations, nucleotides and Pi bind to the catalytic sites of F1, and the membrane 
potential and pH regulate the catalytic activity, as well as IF1 binding; however, the underlying 
conformational changes responsible for PTP formation are still far from being characterized. 
Interestingly, OSCP contains one conserved histidine residue (His 112 in the bovine enzyme) 
exposed to the matrix and located in one of the lowest surface potential regions (Figure 2), which 
could be involved in the regulation of PTP by pH and ROS. In fact, previous studies highlighted  
an essential role of matrix-exposed histidine residue(s) in PTP regulation; histidine protonation at low 
pH indeed induced CyPD release and PTP closure [132,136]. Moreover, in vitro experiments 
demonstrated that oxidation of critical histidine residue(s) located on the PTP matrix side by singlet 
oxygen photogenerated in situ favored the PTP closed conformation by causing a secondary drop of 
reactivity to the cross-linking of pore-activating cysteine residues [137]. OSCP also contains a unique 
cysteine (Cys 118 in bovine mitochondria) conserved in mammals, whose function in ATP synthase 
catalysis is unclear [69]. We suspect that this residue may be involved in PTP activation by forming a 
dithiol cross-linking with a cysteine of another matrix protein, possibly only when His 112 is not 
oxidized. On the other hand, ATP synthase from various organisms is susceptible to different ROS 
species produced in in vitro experiments [138–140], as well as to oxidative/nitrative stress associated 
with central nervous system (CNS) disorders [141,142], caloric restriction [143] and aging [144,145]. 
We showed that isolated F1 from bovine heart ATP synthase is selectively inactivated by hydrogen 
peroxide through redox-active iron-protein adducts, probably generating highly reactive oxygen 
species [139]. More recently, an exclusive target of singlet oxygen and hydrogen peroxide has been 
identified in a highly conserved methionine-cysteine cluster of the chloroplast γ subunit that is 
essential for the enzyme coupling and whose oxidation appeared to be directly involved in the loss of 
enzyme activity [146]. Due to its conservation, it is tempting to hypothesize that also this cluster may 
be a candidate for ROS-mediated PTP modulation. Other selective ATP synthase targets of ROS may 
be three of the five Trp residues of the d subunit identified in human heart mitochondria [147]  
and a single Trp of the α subunit identified in Podospora anserina and possibly involved in protein 
quality control [148]. Their oxidation may occur as a consequence of PTP formation. Moreover, in 
Podospora anserina, an age-related post-translational modification of OSCP has been identified  
by 2D-PAGE and matrix-assisted laser desorption/ionization-Time-of-Flight mass spectrometry 
(MALDI-TOF MS) whose nature is still to be clarified [144]. 
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Figure 2. Surface potential regions on OSCP. The two lowest potential regions on OSCP 
are highlighted by a yellow circle. The average surface atom potential is displayed on the 
left; the cartoon structure is shown on the right with positively (blue) and negatively (red) 
charged side chains. The color code for the potential is: saturated red, −8.0 kJ/(mol·q); 
saturated blue, 8.0 kJ/(mol·q). The F1 structure is shown as transparent. The yellow circle 
in the upper panel is located at OSCP residues E48, D71, E76 and F78. The latter region, 
discussed in the text, encompasses Helices 3 and 4. For the sake of completeness, the 
yellow circle in the lower panel is located at the other lowest potential region located at 
OSCP residues H112, E115, V116, E128 and E133. The surface potential is computed as 
previously described [4,149]. 
 
6. Concluding Remarks 
Through its contacts with the F1 α3β3 hexamer and the peripheral stalk, OSCP not only ensures the 
structural and functional coupling between FO and F1, which is necessary for ATP synthesis, but also 
modulates the enzyme complex and is the target of inhibitors and interactors, including CyPD. CyPD 
affects ATP synthase activity and, most importantly, decreases the threshold matrix Ca2+ required for 
PTP opening. This finding, together with the electrophysiological demonstration that ATP synthase 
dimers give rise to Ca2+-dependent currents with features indistinguishable from those of the PTP, 
indicate that ATP synthase is directly involved in PTP formation and that OSCP plays a fundamental 
role in this process, acting as a sensor for signal(s) that switch the enzyme of life in a channel able to 
induce cell death. CyPD and OSCP are the targets of signaling pathways (such as phosphorylation and 
acetylation) and of common interactors (such as Hsp90). Many open questions remain, in particular:  
(i) How does CyPD interaction with OSCP change the apparent affinity of the ATP synthase for Ca2+, 
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triggering a conformational change that leads to PTP formation? (ii) Where is (are) the Ca2+ binding 
site(s)? (iii) Is the redox sensitivity of the transition of the ATP synthase to PTP formation mediated by 
a dithiol-disulfide interconversion, and where are the relevant cysteines located? (iv) Is the  
pH-dependent inhibition of the PTP due to IF1 binding, which is pH-dependent? These and many other 
questions can now be addressed with the powerful methods of genetics, and we have little doubt that 
the future has a lot in store toward our molecular understanding of the permeability transition. 
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